JP2009522371A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522371A5
JP2009522371A5 JP2008549616A JP2008549616A JP2009522371A5 JP 2009522371 A5 JP2009522371 A5 JP 2009522371A5 JP 2008549616 A JP2008549616 A JP 2008549616A JP 2008549616 A JP2008549616 A JP 2008549616A JP 2009522371 A5 JP2009522371 A5 JP 2009522371A5
Authority
JP
Japan
Prior art keywords
treatment
patients
nitazoxanide
hepatitis
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522371A (ja
JP5185826B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000574 external-priority patent/WO2007081974A2/en
Publication of JP2009522371A publication Critical patent/JP2009522371A/ja
Publication of JP2009522371A5 publication Critical patent/JP2009522371A5/ja
Application granted granted Critical
Publication of JP5185826B2 publication Critical patent/JP5185826B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008549616A 2006-01-09 2007-01-09 ウイルス性肝炎の処置 Expired - Fee Related JP5185826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
US60/757,036 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009293398A Division JP2010070566A (ja) 2006-01-09 2009-12-24 ウイルス性肝炎の処置

Publications (3)

Publication Number Publication Date
JP2009522371A JP2009522371A (ja) 2009-06-11
JP2009522371A5 true JP2009522371A5 (https=) 2010-02-18
JP5185826B2 JP5185826B2 (ja) 2013-04-17

Family

ID=38257004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008549616A Expired - Fee Related JP5185826B2 (ja) 2006-01-09 2007-01-09 ウイルス性肝炎の処置
JP2009293398A Pending JP2010070566A (ja) 2006-01-09 2009-12-24 ウイルス性肝炎の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009293398A Pending JP2010070566A (ja) 2006-01-09 2009-12-24 ウイルス性肝炎の処置

Country Status (17)

Country Link
US (3) US8633230B2 (https=)
EP (1) EP1976516B9 (https=)
JP (2) JP5185826B2 (https=)
CN (1) CN101448497B (https=)
AP (1) AP2907A (https=)
AU (1) AU2007204963B2 (https=)
BR (1) BRPI0706379A2 (https=)
CA (1) CA2636527C (https=)
DK (1) DK1976516T3 (https=)
EA (1) EA015560B1 (https=)
ES (1) ES2422556T3 (https=)
IL (1) IL192548A (https=)
MX (1) MX2008008723A (https=)
NZ (1) NZ569507A (https=)
UA (1) UA100840C2 (https=)
WO (1) WO2007081974A2 (https=)
ZA (1) ZA200806310B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
SI2395840T1 (sl) * 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
EP2408770B1 (en) 2009-03-20 2014-11-05 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
US9333193B2 (en) 2010-09-20 2016-05-10 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
MX2017006083A (es) 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
PT3436074T (pt) 2016-03-31 2020-08-21 Romark Laboratories Lc Compostos tiazolida para tratamento de infeções virais
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
JP6894923B2 (ja) * 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
US11033534B2 (en) * 2017-01-27 2021-06-15 Genfit Pharmaceutical compositions for combination therapy
WO2018167103A1 (en) * 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター，ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
CA3130713A1 (en) 2019-04-09 2020-10-15 Peggy Parroche Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
US20230303504A1 (en) 2020-07-20 2023-09-28 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) * 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
PL186504B1 (pl) 1994-04-13 2004-01-30 Romark Lab Pochodne benzamidowe i kompozycje farmaceutyczne zawierające te pochodne
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) * 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
CN100515420C (zh) * 1997-05-07 2009-07-22 罗马克实验室有限公司 脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物
US5935591A (en) * 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
AU766597B2 (en) * 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
US5925622A (en) * 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
EP1562617B1 (en) 2002-10-29 2006-12-20 Council of Scientific and Industrial Research New use of pipataline
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
EA200501524A1 (ru) * 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) * 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
SI2395840T1 (sl) * 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem

Similar Documents

Publication Publication Date Title
JP5185826B2 (ja) ウイルス性肝炎の処置
JP2009522371A5 (https=)
US20100260755A1 (en) Ibudilast and immunomodulators combination
AU2010313497B2 (en) Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
US20240342211A1 (en) Short-term activated dc1s and methods for their production and use
US11007178B2 (en) Methods and uses of Nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof
JP2008515816A (ja) カスタノスペルミンを含有する、併用抗ウイルス組成物およびその使用方法
EA015799B1 (ru) Режим применения кладрибина для лечения рассеянного склероза
WO2010009762A1 (en) Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection
WO2022213870A1 (zh) 通过口服给药抑制CD4+Treg细胞的药物和方法
HK1123733B (en) Viral hepatitis treatment
CN112569359A (zh) 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
RU2597795C2 (ru) Ингибитор скопления жидкости в полостях организма
JP5527549B2 (ja) Ｃ型肝炎治療剤
JP2004155777A (ja) Ｃ型慢性肝炎治療剤
KR20220082862A (ko) 혈액 악성 종양을 치료하기 위한 병용 요법
CN1364089A (zh) Cml的治疗
HK1185808A1 (zh) 用於治疗癌症的包含威罗菲尼和干扰素的组合疗法
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
TW201110976A (en) Medicinal agent and method for treatment of intractable chronic hepatitis c